Brittany N. Chao

Brittany N. Chao

Auto-generated profile, based on publicly available information

Brittany N. Chao

Division of Virology, Department of Pathology, University of Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2014 in Nature Communications
Verified
Journal Article
Open access
PDF file
WLWei Lu
Wei Lu
Senthilkumar S. KaruppagounderSenthilkumar S. Karuppagounder
Senthilkumar S. Karuppagounder
DSDanielle A. Springer
Danielle A. Springer
MAMichele D. Allen
Michele D. Allen
LZLixin Zheng
Lixin Zheng
MLMichael Lenardo
Michael Lenardo
Mitophagy is a specialized form of autophagy that selectively disposes of dysfunctional mitochondria. Delineating the molecular regulation of mitophagy is of great importance because defects in this process lead to a variety of mitochondrial diseases. Here we report that mice deficient for the mitochondrial protein, phosphoglycerate mutase family member 5 (PGAM5), displayed a Parkinson’s-like movement phenotype. We determined biochemically that PGAM5 is required for the stabilization of the mitophagy-inducing protein PINK1 on damaged mitochondria. Loss of PGAM5 disables PINK1-mediated mitophagy in vitro and leads to dopaminergic neurodegeneration and mild dopamine loss in vivo. Our data indicate that PGAM5 is a regulator of mitophagy essential for mitochondrial turnover and serves a cytoprotective function in dopaminergic neurons in vivo. Moreover, PGAM5 may provide a molecular link to study mitochondrial homeostasis and the pathogenesis of a movement disorder similar to Parkinson’s disease.

1 April 2014 in Cell Host & Microbe
Verified
Journal Article
Closed access
BFBruno Frederico
Bruno Frederico
BCBrittany Chao
Brittany Chao
JMJanet S. May
Janet S. May
GBGabrielle T. Belz
Gabrielle T. Belz
PSPhilip G. Stevenson
Philip G. Stevenson

1 August 2015 in Journal of General Virology
Verified
Journal Article
Open access
BFBruno Frederico
Bruno Frederico
BCBrittany Chao
Brittany Chao
CLClara Lawler
Clara Lawler
JMJanet S. May
Janet S. May
PSPhilip G. Stevenson
Philip G. Stevenson
Lymphocyte proliferation, mobility and longevity make them prime targets for virus infection. Myeloid cells that process and present environmental antigens to lymphocytes are consequently an important line of defence. Subcapsular sinus macrophages (SSMs) filter the afferent lymph and communicate with B-cells. How they interact with B-cell-tropic viruses is unknown. We analysed their encounter with murid herpesvirus-4 (MuHV-4), an experimentally accessible gammaherpesvirus related to Kaposi's sarcoma-associated herpesvirus. MuHV-4 disseminated via lymph nodes, and intranasally or subcutaneously inoculated virions readily infected SSMs. However, this infection was poorly productive. SSM depletion with clodronate-loaded liposomes or with diphtheria toxin in CD169–diphtheria toxin receptor transgenic mice increased B-cell infection and hastened virus spread to the spleen. Dendritic cells provided the main route to B-cells, and SSMs slowed host colonization, apparently by absorbing virions non-productively from the afferent lymph.

20 November 2015 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
BCB. N. Chao
B. N. Chao
WBW. H. Baldwin
W. H. Baldwin
JHJ. F. Healey
J. F. Healey
EPE. T. Parker
E. T. Parker
KSK. Shafer‐Weaver
K. Shafer‐Weaver
MLM. J. Lenardo
M. J. Lenardo
Essentials Anti‐factor VIII (FVIII) inhibitory antibody formation is a severe complication in hemophilia A therapy. We genetically engineered and characterized a mouse model with complete deletion of the F8 coding region. F8TKO mice exhibit severe hemophilia, express no detectable F8 mRNA, and produce FVIII inhibitors. The defined background and lack of FVIII in F8TKO mice will aid in studying FVIII inhibitor formation. Summary Background The most important complication in hemophilia A treatment is the development of inhibitory anti‐Factor VIII (FVIII) antibodies in patients after FVIII therapy. Patients with severe hemophilia who express no endogenous FVIII (i.e. cross‐reacting material, CRM) have the greatest incidence of inhibitor formation. However, current mouse models of severe hemophilia A produce low levels of truncated FVIII. The lack of a corresponding mouse model hampers the study of inhibitor formation in the complete absence of FVIII protein. Objectives We aimed to generate and characterize a novel mouse model of severe hemophilia A (designated the F8TKO strain) lacking the complete coding sequence of F8 and any FVIII CRM. Methods Mice were created on a C57BL/6 background using Cre‐Lox recombination and characterized using in vivo bleeding assays, measurement of FVIII activity by coagulation and chromogenic assays, and anti‐FVIII antibody production using ELISA. Results All F8 exonic coding regions were deleted from the genome and no F8 mRNA was detected in F8TKO mice. The bleeding phenotype of F8TKO mice was comparable to E16 mice by measurements of factor activity and tail snip assay. Similar levels of anti‐FVIII antibody titers after recombinant FVIII injections were observed between F8TKO and E16 mice. Conclusions We describe a new C57BL/6 mouse model for severe hemophilia A patients lacking CRM. These mice can be directly bred to the many C57BL/6 strains of genetically engineered mice, which is valuable for studying the impact of a wide variety of genes on FVIII inhibitor formation on a defined genetic background.

13 May 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
YYYikun Yao
Yikun Yao
PJPing Du Jiang
Ping Du Jiang
BCBrittany N. Chao
Brittany N. Chao
DCDeniz Cagdas
Deniz Cagdas
SKSatoshi Kubo
Satoshi Kubo
MLMichael J. Lenardo
Michael J. Lenardo
Inborn errors of immunity (IEIs) unveil regulatory pathways of human immunity. We describe a new IEI caused by mutations in the GTPase of the immune-associated protein 6 (GIMAP6) gene in patients with infections, lymphoproliferation, autoimmunity, and multiorgan vasculitis. Patients and Gimap6−/− mice show defects in autophagy, redox regulation, and polyunsaturated fatty acid (PUFA)–containing lipids. We find that GIMAP6 complexes with GABARAPL2 and GIMAP7 to regulate GTPase activity. Also, GIMAP6 is induced by IFN-γ and plays a critical role in antibacterial immunity. Finally, we observed that Gimap6−/− mice died prematurely from microangiopathic glomerulosclerosis most likely due to GIMAP6 deficiency in kidney endothelial cells.

30 April 2022 in Metabolomics
Verified
Journal Article
Open access
PDF file
CYCatherine T. Yu
Catherine T. Yu
BCBrittany N. Chao
Brittany N. Chao
RBRolando Barajas
Rolando Barajas
MHMajda Haznadar
Majda Haznadar
PMPadma Maruvada
Padma Maruvada
Krista ZanettiKrista Zanetti
Krista Zanetti
Background: Through the systematic large-scale profiling of metabolites, metabolomics provides a tool for biomarker discovery and improving disease monitoring, diagnosis, prognosis, and treatment response, as well as for delineating disease mechanisms and etiology. As a downstream product of the genome and epigenome, transcriptome, and proteome activity, the metabolome can be considered as being the most proximal correlate to the phenotype. Integration of metabolomics data with other -omics data in multi-omics analyses has the potential to advance understanding of human disease development and treatment. Aim of review: To understand the current funding and potential research opportunities for when metabolomics is used in human multi-omics studies, we cross-sectionally evaluated National Institutes of Health (NIH)-funded grants to examine the use of metabolomics data when collected with at least one other -omics data type. First, we aimed to determine what types of multi-omics studies included metabolomics data collection. Then, we looked at those multi-omics studies to examine how often grants employed an integrative analysis approach using metabolomics data. Key scientific concepts of review: We observed that the majority of NIH-funded multi-omics studies that include metabolomics data performed integration, but to a limited extent, with integration primarily incorporating only one other -omics data type. Some opportunities to improve data integration may include increasing confidence in metabolite identification, as well as addressing variability between -omics approach requirements and -omics data incompatibility.